Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2CNS 2Sarcoma 1

Conditions

Neuroendocrine Tumors 5Pheochromocytoma 2Paraganglioma 2Meningioma 2Medulloblastoma 2Glioma 2Ependymoma 2Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

lutetium Lu 177 dotatate 2olaparib 1gallium Ga 68 dotatate 1Nivolumab 1Iodine-131 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pheochromocytoma × lutetium Lu 177 dotatate × Clear all
NCT06607692 2026-06-04

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡